Story perspectives

Eli Lilly’s Oral JAK2 Cuts Spleen 70%, Improves Symptoms.

6/15/2026

Summary

Story summary

Eli Lilly announced its oral type II JAK2 inhibitor AJ1-11095 showed results indicating meaningful improvement for myelofibrosis patients in a Phase 1 trial of 23 participants.
Seventy percent of patients achieved spleen volume reduction >=35 % and symptom burden improvement >=50 % by week 12.
Variant allele frequency fell in 21 patients, reaching a >=20 % drop in 59% and a >=50 % drop in 35% by week 24, with safety manageable and 78% staying on study.

1 of 1

Story summary

Eli Lilly announced its oral type II JAK2 inhibitor AJ1-11095 showed results indicating meaningful improvement for myelofibrosis patients in a Phase 1 trial of 23 participants.
Seventy percent of patients achieved spleen volume reduction >=35 % and symptom burden improvement >=50 % by week 12.
Variant allele frequency fell in 21 patients, reaching a >=20 % drop in 59% and a >=50 % drop in 35% by week 24, with safety manageable and 78% staying on study.